Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-
cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized …

PURPOSE Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in
25% to 30% of patients, with better overall survival (OS) than that for advanced-stage …

Autoimmune diseases (ADs) are a broad range of disorders which are characterized by long-
term inflammation and tissue damage arising from an immune response against one's own …

Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma
(DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab …

Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET,
hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell …

The clinical and immunological impact of B‐cell depletion in the context of coronavirus
disease 2019 (COVID‐19) is unclear. We conducted a prospectively planned analysis of …

High-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), is a recently introduced
diagnostic category for aggressive B-cell lymphomas. It includes tumors with Burkitt-like or …

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized
in 25% to 30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is …